No bonuses for Novavax following failed RSV vaccine trial

With a brutal blow from a failed RSV vaccine trial for elderly patients, last year wasn't a great one for Gaithersburg-based Novavax. And the compnay's new proxy statement shows a little more about how the company (NASDAQ: NVAX) reacted. The company eliminated cash bonuses last year for all employees, including senior executives, the Securities and Exchange Commission filing shows. Novavax also said senior executives would not r eceive annual salary increases this year and had their 2017 stock option…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news